Scientists have discovered that a medication already approved for treating multiple sclerosis and psoriasis shows remarkable promise in combating periodontitis, one of the leading causes of tooth loss worldwide.

Researchers from Wenzhou Medical University found that dimethyl fumarate (DMF) significantly reduced bone loss and inflammation in experimental models of gum disease by improving cellular “cleanup” mechanisms and shifting immune responses toward healing rather than destruction.

“Dimethyl fumarate’s ability to fine-tune macrophage polarization through mitophagy is a game-changer in periodontal therapy,” said Dr. Shengbin Huang, the study’s corresponding author. “By targeting the mitochondrial protein TUFM, we uncovered a molecular switch that controls the inflammatory response in gum tissue. These insights could redefine how we treat chronic inflammatory conditions beyond the oral cavity.”